[1] |
XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin.
Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
|
[2] |
XIAO Yue, LI Tangfei, XUE Qianfu.
Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
|
[3] |
JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin.
Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
|
[4] |
LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai.
Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
|
[5] |
LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong.
Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
|
[6] |
YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong.
Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
|
[7] |
BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong.
Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
|
[8] |
HUANG Yiting, SHEN Aizong.
Clinical research progress of afatinib therapy for lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
|
[9] |
LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang.
Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
|
[10] |
PAN Luping, SHI Wujie, SHEN Zhipeng.
Efficacy and safety of etoposide combined with carboplatin in children with recurrent medulloblastoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 189-195.
|
[11] |
SHI Lili, LIU Xingan, SHAN Guoyong.
Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
|
[12] |
YANG Haijing, YU Jicheng, WANG Jingjing, LI Nanyang, WU Jufang, ZHANG Hai, XUE Tao, DAI Weiguo, DING Tianling, CAO Guoying.
Risk management of biological agents in phase I clinical trials: Case sharing
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 44-48.
|
[13] |
HUA Xudan, XIE Hongyi, YU Shufang.
Analysis of the efficacy, safety and economics of prophylactic antibiotics in high-risk neonates guided by C reaction protein and procalcitonin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 561-566.
|
[14] |
WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian.
Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.
|
[15] |
SONG Xin, WANG Xue, ZHOU Huanghong, ZHAO Tianyi.
Effect of compound glycyrrhizin on the expression and clinical prognosis of antibacterial peptide LL-37 in patients with pigmentary purpuric skin disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 458-463.
|